Grafts enriched for CD34+ hematopoietic progenitor cells are finding growing clinical applications for both autologous and allogenic transplantation: Hematopoietic rescue following high-dose and dose-intensive chemotherapy for high-risk patients with both hematologic malignancies and solid tumors. In allogenic transplantation, CD34 selection can provide hematopoietic cells that support haematological recovery and can serve to reduce the number of T cells in transplant grafts that have role in causing rejection. Selection procedure followed by Transcell entails no alteration to target cell structure or function while the selection process in the closed system allows rapid, uniform preparation of transplant grafts with greater reproducibility and methodological standardization in treating cancers

Most haploidentical transplantation strategies require profound T cell depletion of the graft to minimize the risk for GVHD. Strategies involve transplanting CD34+ enriched hematopoietic cells allowing the indirect and custom specified removal of whole T cells facilitated by Transcell

Natural Killer (NK) cells recognize and rapidly act against any residual malignant cells to curb any relapse. Upon activation, NK cells release cytotoxic granules containing perforin and granzymes to directly digest tumor cells and eliminate them. They are also potent producers of chemokines and cytokines such as interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) and so are essential in modulating adaptive immune responses. NK cells originate from CD34+ HSCs and can be cultured, activated in the in vitro set up (identified by the absence of CD3 and the presence of CD56 on their surface), cryopreserved to thaw and formulate the therapeutic dosage for clinical application